Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX-02 in Alport Syndrome with Nonsense Mutations
NCT05448755Phase 2Completed
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of exaluren in Alport syndrome. Primary endpoint: Number of Participants With Adverse Events at 5 months. Started Nov 2022; status: completed.
02
Drugs
exaluren
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT05448755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448755.